OncoMatch/Clinical Trials/NCT06308588
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Is NCT06308588 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Blinatumomab and Asciminib for philadelphia chromosome-positive.
Treatment: Blinatumomab · Asciminib — To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: ABL1 fusion
Required: BCR fusion
Disease stage
Required: Stage RELAPSED, REFRACTORY, PREVIOUSLY UNTREATED, MINIMALLY PRETREATED
previously untreated or minimally pretreated Ph-positive ALL ... relapsed/refractory Ph-positive ALL ... previously treated lymphoid blast phase CML
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: investigational antileukemic agents
Exception: unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator
Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator
Cannot have received: chemotherapy
Exception: Cytarabine 2 g/m2 (or alternative) for cytoreduction is permitted
Treatment with any ... chemotherapy agents in the last 7 days before study entry ... Cytarabine 2 g/m2 (or alternative) for cytoreduction is permitted
Lab requirements
Kidney function
Creatinine clearance ≥30 mL/min
Liver function
Total serum bilirubin ≤ 2 x ULN (unless due to Gilbert's syndrome); ALT ≤ 3 x ULN OR AST ≤ 3 x ULN
Cardiac function
Adequate cardiac function as assessed clinically by history and physical examination
Adequate liver function as defined by ... Total serum bilirubin ≤ 2 x ULN ... ALT ≤ 3 x ULN OR AST ≤ 3 x ULN ... Adequate renal function defined as: Creatinine clearance ≥30 mL/min ... Adequate cardiac function as assessed clinically by history and physical examination
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify